Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 March 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Noninvasive markers of liver fibrosis in drug users with Hep C

FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis in injection drug users with Hep C, reports this month's Hepatology.

News image

fiogf49gjkf04

Most Hepatitis C virus infections are acquired by injection drug use.

Dr Lucy Wilson and colleagues from the USA assessed prospective data on the progression of liver fibrosis.

Baseline liver biopsies were obtained from 1996 to 1998 on a random sample of 210 out of 1667 Hepatitis C virus-positive injection drug users.

Subjects were followed biannually, with a second biopsy offered to those eligible.

Among 119 prospectively followed injection drug users, 96% were African American, and 97% were Hepatitis C virus genotype 1a/b.

A further 27% were HIV-infected, with a median age of 42 years.

Paired biopsies were scored from 0 to 6.

The research team defined significant fibrosis was as score 3 or greater.

Progression of fibrosis was defined as an increase 2 or more units or clinical evidence of end-stage liver disease.

The predictive value for alanine aminotransferase specificities was 73%
Hepatology

The team's predictive values of blood markers include FibroSURE, aspartate aminotransferase-to-platelet-ratio index and alanine aminotransferase.

The researchers assessed the detection of contemporaneous and future liver fibrosis.

The team noted that 91% did not have significant liver fibrosis at first biopsy.

The researchers' predictive value for detecting insignificant fibrosis at first biopsy was greater than 95% for FibroSURE.

The predictive value for aminotransferase-to-platelet-ratio index, and alanine aminotransferase specificities were 73%.

After 4 years median follow-up, 21% had progression of fibrosis.

The researchers observed that this was significantly associated with serum level of Hepatitis C virus RNA and alanine aminotransferase.

No serological test had a predictive value greater than 40% for contemporaneous or future significant fibrosis.

Initial biopsy result had only a 30% value for predicting future significant fibrosis.

Dr Wilson's team concluded, “Significant liver fibrosis and progression were detected in some, but not most, injection drug users in this cohort.”

“In this setting with low fibrosis prevalence, FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis.”

“However, further work is needed to find noninvasive markers of significant liver fibrosis.”

Hepatol 2006: 43(4): 788-95
05 April 2006

Go to top of page Email this page Email this page to a colleague

 24 March 2017 
Prevalence of undiagnosed celiac disease
 24 March 2017 
MRI for local staging of colon cancer
 24 March 2017 
In-office communication about ulcerative colitis
 23 March 2017 
H. pylori and GERD in children
 23 March 2017 
Prespectives on the management of fecal incontinence
 23 March 2017 
Suspected nonceliac gluten sensitivity
 22 March 2017 
Abdominal visceral fat and new erosive esophagitis
 22 March 2017 
Role of microbiota in colorectal surgery
 22 March 2017 
Disease activity in eosinophilic esophagitis
 21 March 2017 
Hepatitis C virus–related hepatic myelopathy
 21 March 2017 
Global trends in colorectal cancer mortality
 21 March 2017 
Pain in pancreatic cancer
 20 March 2017 
Metastasis in human colorectal cancer
 20 March 2017 
Fistula treatment of Crohn’s disease
 20 March 2017 
NASH treatment and MRI
 17 March 2017 
Acute liver failure in Scotland
 17 March 2017 
Microbiota in colorectal cancer 
 17 March 2017 
Among Persons with IBD
 16 March 2017 
Hepatocellular carcinoma risk in different etiologies of cirrhosis
 16 March 2017 
IBD disability index
 16 March 2017 
Transition readiness scores in adolescents with IBD
 15 March 2017 
European consensus on fecal microbiota transplantation 
 15 March 2017 
Hepatocellular carcinoma in the USA 
 15 March 2017 
Hospital readmission for ulcerative colitis
 14 March 2017 
Cardiovascular diseases risk in Barrett's
 14 March 2017 
Assessment of competence in colonoscopy
 14 March 2017 
Cholecystectomy to prevent recurrent pancreatitis
 13 March 2017 
Gallstone disease after colectomy for ulcerative colitis
 13 March 2017 
Achalasia in Chicago since high-resolution manometry
 13 March 2017 
Vedolizumab exposure in pregnancy
 10 March 2017 
Thiopurine therapy in IBD
 10 March 2017 
Complications in advanced fibrosis in Hep C eradication
 10 March 2017 
Intragastric balloons for obesity-related co-morbidities
 09 March 2017 
Intestinal tuberculosis vs Crohn's disease
 09 March 2017 
Predictors of relapse in children with IBD
 09 March 2017 
Direct-acting antiviral regimen for Hep C genotype 3 
 08 March 2017 
Sterile fecal filtrate transfer for C. diff
 08 March 2017 
Drug-induced liver injury
 08 March 2017 
Pharmacotherapy for alcohol dependence
 07 March 2017 
Psychotropic drugs in functional dyspepsia
 07 March 2017 
Vagus nerve and appetite regulation
 07 March 2017 
Gastrointestinal involvement in systemic sclerosis
 06 March 2017 
Small bowel abnormalities in IBS 
 06 March 2017 
Treatment response in NASH with MRI
 06 March 2017 
Intestinal bacterial overgrowth and PPIs in children
 03 March 2017 
Alcohol and risk of gallstone disease
 03 March 2017 
Smoking at colon cancer diagnosis influences survival
 03 March 2017 
Improvements in Crohn’s Disease outcomes over time
 02 March 2017 
Surviving sepsis guidelines
 02 March 2017 
Tenofovir and Hep B transmission in pregnancy
 02 March 2017 
Diagnosis of pediatric IBD 
 01 March 2017 
Healthcare utilization amonth IBD Veterans
 01 March 2017 
Complications after ileocecal resection in Crohn’s
 01 March 2017 
Fecal microbiotica transplnantation

 28 February 2017 
Smoking and cancer-specific survival in colon cancer
 28 February 2017 
ALT levels and all-cause mortality
 28 February 2017 
American Gastroenterological Association for acute liver failure
 27 February 2017 
Hep B cure research
 27 February 2017 
Elemental diet in adult eosinophilic esophagitis patients
 27 February 2017 
Eluxadoline in IBS-diarrhea

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us